drugset / Trial / NCT00061802
Efficacy and Safety of Two Atypical Antipsychotics vs. Placebo in Patients With an Acute Exacerbation of Either Schizophrenia or Schizoaffective Disorder
Phase 4
Completed
225 enrolled
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Janssen, LP · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
A study to evaluate the efficacy and safety of two atypical antipsychotics vs. placebo in patients with an acute exacerbation of either schizophrenia or schizoaffective disorder
Timeline
- Start
- 2003-06
- Primary completion
- —
- Completion
- 2004-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Quetiapine | Small molecule | 400 mg | — |
| Subject | Quetiapine | Small molecule | 600 mg | — |
| Subject | Quetiapine | Small molecule | 800 mg | — |
| Subject | Risperidone | Other / unclassified | 4 mg | — |
| Subject | Risperidone | Other / unclassified | 6 mg | — |